An open label study to evaluate safety, tolerability and clinical utility of ULTRACET (37.5mg tramadol hydrochloride/325mg acetaminophen [tramadol/paracetamol]) for the treatment of breakthrough pain in cancer patients.

Trial Profile

An open label study to evaluate safety, tolerability and clinical utility of ULTRACET (37.5mg tramadol hydrochloride/325mg acetaminophen [tramadol/paracetamol]) for the treatment of breakthrough pain in cancer patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 May 2009

At a glance

  • Drugs Tramadol/paracetamol (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Johnson & Johnson
  • Most Recent Events

    • 06 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top